Alzheimer’s disease is the most common cause of neurocognitive disorder, a diagnostic category used in both the DSM-5 and the ICD-11 to describe conditions that impair thinking, memory, and daily functioning. The term “neurocognitive disorder” replaced the older label “dementia” in modern diagnostic systems, though both words still appear in clinical practice. Alzheimer’s accounts for roughly 60 to 80 percent of all neurocognitive disorder cases.
What “Neurocognitive Disorder” Actually Means
The DSM-5, the primary diagnostic manual used by mental health professionals, groups conditions that damage cognitive ability under the umbrella of neurocognitive disorders. Clinicians evaluate six specific cognitive domains to determine whether someone qualifies: complex attention, learning and memory, executive ability, language, visuoconstructional-perceptual ability, and social cognition. A decline in one or more of these domains, confirmed by testing and noticeable in everyday life, points toward a neurocognitive disorder diagnosis.
The classification has two levels. Mild neurocognitive disorder describes a stage where cognitive changes are measurable but the person can still manage daily activities independently, sometimes with extra effort or compensating strategies. Major neurocognitive disorder is the more severe form, where cognitive decline interferes significantly with independence. What most people think of as “dementia” maps onto major neurocognitive disorder.
Alzheimer’s fits into this framework as the underlying cause. A clinician would diagnose someone with “major neurocognitive disorder due to Alzheimer’s disease” or “mild neurocognitive disorder due to Alzheimer’s disease,” depending on how far the condition has progressed.
How Alzheimer’s Is Classified Internationally
The ICD-11, the World Health Organization’s coding system used in hospitals and health records worldwide, follows a similar structure. It lists dementia due to Alzheimer’s disease under code 6D80 within its neurocognitive disorders chapter. The system distinguishes between early-onset Alzheimer’s (before age 65) and late-onset (after 65), and recognizes mixed forms where Alzheimer’s coexists with vascular damage or other brain diseases.
A significant update in ICD-11 is the addition of mild neurocognitive disorder (code 6D71), which can be linked to Alzheimer’s as the underlying cause. This matters because it allows doctors to formally diagnose Alzheimer’s at an earlier stage, before it progresses to full dementia. That earlier diagnosis opens the door to disease-modifying treatments that work best when started sooner. Previously, diagnostic codes only captured the dementia stage, leaving the earlier phase in a gray zone.
One quirk of the ICD-11: the psychiatric chapter uses syndrome-based labels like “dementia due to Alzheimer’s disease,” while the neurology chapter uses the disease term “Alzheimer’s disease” on its own. Both refer to the same condition, just viewed from different clinical angles.
How Alzheimer’s Is Diagnosed Biologically
The 2024 criteria from the National Institute on Aging and Alzheimer’s Association represent a major shift in how Alzheimer’s is defined. Under these guidelines, Alzheimer’s is defined by its biology rather than its symptoms. Biomarker evidence of specific brain changes is enough for diagnosis, even before a person shows noticeable cognitive decline.
The key biological markers fall into two groups. Core-1 biomarkers, which include signs of amyloid buildup and early-stage tau protein changes, are used to confirm an Alzheimer’s diagnosis. These can be detected through brain imaging scans, spinal fluid tests, or validated blood tests that measure specific forms of tau protein. Core-2 biomarkers track later-stage tau buildup and are used mainly for staging how far the disease has progressed.
The updated framework also accounts for the messiness of real-world brain disease. It tracks inflammation, nerve cell loss, proteins associated with Parkinson’s-like pathology, and vascular injury alongside the core Alzheimer’s markers. This reflects what clinicians see in practice: most people with late-life cognitive decline have more than one type of brain pathology contributing to their symptoms.
How Alzheimer’s Progresses Through NCD Stages
Alzheimer’s typically begins in the mild neurocognitive disorder stage, where a person might forget recent conversations, struggle to find words, or need more time to complete familiar tasks. At this point, they can still live independently. The progression from this mild stage to major neurocognitive disorder (dementia) is not guaranteed in the short term, but the odds are high. Research tracking over 3,500 cases found an annual progression rate of about 15.7% from mild cognitive impairment to clinical dementia.
When the underlying cause is specifically Alzheimer’s, progression tends to be faster than in other types of cognitive impairment. In one study, 54 out of 59 people diagnosed with mild cognitive impairment due to Alzheimer’s eventually progressed to full Alzheimer’s dementia, with only 5 remaining stable in the milder category. The progression rate for Alzheimer’s-related impairment was 53.9%, compared to 35.5% for non-Alzheimer’s causes.
In the major neurocognitive disorder stage, memory loss deepens and extends to long-term memories. People may not recognize family members, lose the ability to communicate effectively, and eventually need help with basic activities like eating and dressing. The ICD-11 allows clinicians to classify this stage as mild, moderate, or severe, and to separately code behavioral symptoms like agitation, apathy, anxiety, or wandering that commonly accompany advanced disease.
How Alzheimer’s Differs From Other Neurocognitive Disorders
Alzheimer’s is just one of several diseases that cause neurocognitive disorder, and its pattern looks different from the others. Alzheimer’s typically causes slow, steady cognitive deterioration. Memory loss is the hallmark, particularly the inability to retain new information. People miss social cues, repeat questions, and forget recent events while the rest of their neurological exam appears normal in early stages. Brain scans show shrinkage in the hippocampus and temporal and parietal regions.
Vascular neurocognitive disorder, the second most common type, follows a different trajectory. It often progresses in a stepwise pattern, with sudden drops in function after strokes or periods of reduced blood flow to the brain. The primary deficits tend to involve executive function (planning, organizing, problem-solving) rather than memory. Neurological exams frequently reveal focal signs like gait disturbances or weakness on one side of the body. Brain scans show areas of infarction or widespread white matter damage rather than the hippocampal shrinkage characteristic of Alzheimer’s.
Lewy body neurocognitive disorder has its own signature: visual hallucinations, fluctuating alertness throughout the day, and movement symptoms similar to Parkinson’s disease. Frontotemporal neurocognitive disorder tends to strike earlier (often in the 50s or 60s) and initially affects personality and behavior rather than memory. Recognizing these distinctions matters because treatment approaches, expected timelines, and caregiving needs vary significantly depending on which disease is driving the cognitive decline.